<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:slash="http://purl.org/rss/1.0/modules/slash/">
  <channel>
    <title>Healthcare industry BW</title>
    <description>Healthcare industry BW</description>
    <generator>Laminas_Feed_Writer 2 (https://getlaminas.org)</generator>
    <link>https://www.gesundheitsindustrie-bw.de/en</link>
    <item>
      <title>Kickoff for the EU-Pathfinder Project HEARTCORE at the NMI</title>
      <description><![CDATA[It goes without saying that new drug compounds should place as little strain on the heart as possible. But how can potential effects be reliably predicted? Researchers from the NMI, Hannover Medical School (project lead), the Universitat Politecnica de Valencia, and industry partners Multi Channel Systems and Foresee Biosystems are tackling this challenge in the new HEARTCORE project.]]></description>
      <pubDate>Tue, 16 Jun 2026 14:14:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/kickoff-eu-pathfinder-project-heartcore-nmi</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/kickoff-eu-pathfinder-project-heartcore-nmi</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Redesigning for Reuse and Re-X - systematically redesigning products for the circular economy and reuse</title>
      <description><![CDATA[Kein Inhalt]]></description>
      <pubDate>Mon, 15 Jun 2026 08:00:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/event/redesigning-reuse-and-re-x-systematically-redesigning-products-circular-economy-and-reuse</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/event/redesigning-reuse-and-re-x-systematically-redesigning-products-circular-economy-and-reuse</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>The University of Freiburg and Nagoya University agree on a joint doctoral programme</title>
      <description><![CDATA[The University of Freiburg and Nagoya University are strengthening their strategic partnership through a joint doctoral programme and the Nagoya University Global Campus, which serves as a permanently staffed representative office in Freiburg.]]></description>
      <pubDate>Fri, 12 Jun 2026 15:46:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/university-freiburg-and-nagoya-university-agree-joint-doctoral-programme</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/university-freiburg-and-nagoya-university-agree-joint-doctoral-programme</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>The Heidelberg and Mannheim University Hospitals consortium has taken first place in the Stern hospital rankings</title>
      <description><![CDATA[For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place.]]></description>
      <pubDate>Fri, 12 Jun 2026 07:25:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-and-mannheim-university-hospitals-consortium-has-taken-first-place-stern-hospital-rankings</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-and-mannheim-university-hospitals-consortium-has-taken-first-place-stern-hospital-rankings</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026</title>
      <description><![CDATA[VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, today announced that its previously announced business combination (“Business Combination”) with Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, was closed successfully (the “Closing”)]]></description>
      <pubDate>Thu, 11 Jun 2026 11:22:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/veraxa-biotech-debut-publicly-traded-company-pioneering-next-generation-cancer-therapies-june-11-2026</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/veraxa-biotech-debut-publicly-traded-company-pioneering-next-generation-cancer-therapies-june-11-2026</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>NEURA Robotics announces record series C of up to $1,4 Billion to accelerate the world's leading physical AI Platform</title>
      <description><![CDATA[ NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure.]]></description>
      <pubDate>Wed, 10 Jun 2026 07:32:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/neura-robotics-announces-record-series-c-1-dollars-4-cents-billion-accelerate-worlds-leading-physical-ai-platform</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/neura-robotics-announces-record-series-c-1-dollars-4-cents-billion-accelerate-worlds-leading-physical-ai-platform</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Can Aztekin receives 2026 Schering Young Investigator Award</title>
      <description><![CDATA[This year’s Schering Young Investigator Award has been awarded to Can Aztekin, a Max-Planck-Research Group Leader at the Friedrich Miescher Laboratory of the Max Planck Society in Tübingen, to recognize his significant work in the field of regenerative biology.]]></description>
      <pubDate>Wed, 10 Jun 2026 07:09:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-aztekin-receives-2026-schering-young-investigator-award</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-aztekin-receives-2026-schering-young-investigator-award</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AI Diagnoses Brain Tumors in Minutes Instead of Weeks</title>
      <description><![CDATA[Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.]]></description>
      <pubDate>Wed, 10 Jun 2026 06:41:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-diagnoses-brain-tumors-minutes-instead-weeks</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-diagnoses-brain-tumors-minutes-instead-weeks</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Potential Biomarker for personalized Leukemia therapy identified</title>
      <description><![CDATA[Researchers at Heidelberg Faculty of Medicine at Heidelberg University, in collaboration with partners from 29 German study centers, have found evidence of a potential biomarker for personalized therapy of acute myeloid leukemia (AML) in a Phase II study. Analyses showed that certain patients could benefit from additional treatment with the drug Motixafortide in addition to standard chemotherapy.]]></description>
      <pubDate>Wed, 03 Jun 2026 07:00:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/potential-biomarker-personalized-leukemia-therapy-identified</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/potential-biomarker-personalized-leukemia-therapy-identified</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Fat hack protects against cell death</title>
      <description><![CDATA[In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis. ]]></description>
      <pubDate>Wed, 03 Jun 2026 06:27:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/fat-hack-protects-against-cell-death</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/fat-hack-protects-against-cell-death</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>New insights into muscle physiology – contactless and three-dimensional</title>
      <description><![CDATA[Contactless measurement of muscle activity and training effects: using highly sensitive quantum sensors, researchers at the Universities of Tübingen and Stuttgart are setting new standards. This technology has the potential to revolutionise clinical diagnostics and optimise training and neuroscience research.]]></description>
      <pubDate>Tue, 02 Jun 2026 07:30:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/news/new-insights-muscle-physiology-contactless-and-three-dimensional</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/news/new-insights-muscle-physiology-contactless-and-three-dimensional</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>New approach to prevent treatment-induced leukemia Protective mechanism against DNA damage caused by chemotherapy and radiotherapy discovered</title>
      <description><![CDATA[In rare cases, cancer treatments can cause serious long-term effects. These include so-called secondary leukemias. This form of blood cancer can develop when chemotherapy or radiotherapy damages the genetic material of healthy cells. A research team led by a scientist from Ulm has now discovered a molecular protective mechanism against such genomic damage: a peptide.]]></description>
      <pubDate>Tue, 02 Jun 2026 07:18:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-prevent-treatment-induced-leukemia-protective-mechanism-against-dna-damage-caused-chemotherapy-and-radiotherapy-dis</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-prevent-treatment-induced-leukemia-protective-mechanism-against-dna-damage-caused-chemotherapy-and-radiotherapy-dis</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Central Institute of Mental Health joins international Lancet Commission on schizophrenia</title>
      <description><![CDATA[Leading scientists are pooling their expertise to further advance research and care for psychotic disorders and to align them more closely with the needs of affected individuals. ]]></description>
      <pubDate>Mon, 01 Jun 2026 11:57:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/central-institute-mental-health-joins-international-lancet-commission-schizophrenia</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/central-institute-mental-health-joins-international-lancet-commission-schizophrenia</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Excellent Doctoral Training Enters Second Funding Phase: Medical Faculties at Heidelberg University Continue Successful Graduate Program in the field of Immunology</title>
      <description><![CDATA[The German Research Foundation (DFG) funds continuation of Research Training Group (RTG) 2727 “Checkpoints of Innate Immunity in Cancer and Tissue Damage”, with around €5,8 million.]]></description>
      <pubDate>Mon, 01 Jun 2026 08:52:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/excellent-doctoral-training-enters-second-funding-phase-medical-faculties-heidelberg-university-continue-successful-graduate-pro</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/excellent-doctoral-training-enters-second-funding-phase-medical-faculties-heidelberg-university-continue-successful-graduate-pro</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>More precise therapeutic agents for neuropsychiatry: The NMI is helping to unravel complex receptor mechanisms</title>
      <description><![CDATA[How can effective treatments for neuropsychiatric disorders be developed without having to accept unwanted side effects? Researchers at the NMI have made an important contribution to this field. In their recent paper, “NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry,” they demonstrate how specifically targeting subunits of the NMDA receptor opens up new avenues for safer medications.]]></description>
      <pubDate>Mon, 01 Jun 2026 07:19:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-precise-therapeutic-agents-neuropsychiatry-nmi-helping-unravel-complex-receptor-mechanisms</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-precise-therapeutic-agents-neuropsychiatry-nmi-helping-unravel-complex-receptor-mechanisms</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>FCI Supports Teaching Concept for the Chemistry of Tomorrow</title>
      <description><![CDATA[The German Chemical Industry Fund (FCI) is supporting the course offering ‘DigiChemJN’ at the Faculty of Chemistry and Pharmacy. DigiChemJN strengthens students’ data literacy by providing them qualifications in data-based research methods, experimental datasets, and artificial intelligence (AI).]]></description>
      <pubDate>Fri, 29 May 2026 17:25:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/fci-supports-teaching-concept-chemistry-tomorrow</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/fci-supports-teaching-concept-chemistry-tomorrow</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>An immune defence guide</title>
      <description><![CDATA[Which cellular processes ensure that immune responses are controlled precisely? A new study by the Institute of Cell Biology and Immunology Thurgau (BITG) and the University of Konstanz decodes a decisive signalling pathway.]]></description>
      <pubDate>Thu, 28 May 2026 18:24:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-defence-guide</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-defence-guide</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>New Emmy Noether Junior Research group investigates the mode of action of Antimetabolite Chemotherapy</title>
      <description><![CDATA[How do antimetabolite cancer drugs damage the genetic material of malignantly transformed cells and thereby destroy them? How might these drugs be used more precisely, particularly in the treatment of pediatric tumors? A new research group led by Dr. Christopher Carnie, a scientist at the Heidelberg Faculty of Medicine at Heidelberg University, will address these questions. ]]></description>
      <pubDate>Wed, 27 May 2026 17:14:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-investigates-mode-action-antimetabolite-chemotherapy</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-investigates-mode-action-antimetabolite-chemotherapy</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Funding for three Collaborative Research Centres at DZHK sites</title>
      <description><![CDATA[The German Research Foundation (DFG) is establishing new Collaborative Research Centres and extending existing research networks. Several DZHK sites are also involved. Particular emphasis is being placed on new research approaches to inflammation and thrombosis.]]></description>
      <pubDate>Wed, 27 May 2026 10:45:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/Funding-for-three-Collaborative-Research-Centres-at-DZHK-sites</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/Funding-for-three-Collaborative-Research-Centres-at-DZHK-sites</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Heidelberg based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)</title>
      <description><![CDATA[Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.]]></description>
      <pubDate>Tue, 26 May 2026 16:59:00 +0000</pubDate>
      <link>https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-based-development-revolutionizes-hepatitis-d-therapy-worldwide-us-food-and-drug-administration-fda-approves-hepatitis</link>
      <guid>https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-based-development-revolutionizes-hepatitis-d-therapy-worldwide-us-food-and-drug-administration-fda-approves-hepatitis</guid>
      <slash:comments>0</slash:comments>
    </item>
  </channel>
</rss>
